Lipid Nanoparticles for Cell-Specific <i>in Vivo</i> Targeted Delivery of Nucleic Acids

DOI Web Site Web Site PubMed 6 Citations 94 References
  • Khalil Ikramy A.
    Faculty of Pharmaceutical Sciences, Hokkaido University Faculty of Pharmacy, Assiut University
  • Younis Mahmoud A.
    Faculty of Pharmaceutical Sciences, Hokkaido University Faculty of Pharmacy, Assiut University
  • Kimura Seigo
    Faculty of Pharmaceutical Sciences, Hokkaido University
  • Harashima Hideyoshi
    Faculty of Pharmaceutical Sciences, Hokkaido University

Bibliographic Information

Other Title
  • Lipid Nanoparticles for Cell-Specific in Vivo Targeted Delivery of Nucleic Acids

Search this article

Abstract

<p>The last few years have witnessed a great advance in the development of nonviral systems for in vivo targeted delivery of nucleic acids. Lipid nanoparticles (LNPs) are the most promising carriers for producing clinically approved products in the future. Compared with other systems used for nonviral gene delivery, LNPs provide several advantages including higher stability, low toxicity, and greater efficiency. Additionally, systems based on LNPs can be modified with ligands and devices for controlled biodistribution and internalization into specific cells. Efforts are ongoing to improve the efficiency of lipid-based gene vectors. These efforts depend on the appropriate design of nanocarriers as well as the development of new lipids with improved gene delivery ability. Several ionizable lipids have recently been developed and have shown dramatically improved efficiency. However, enhancing the ability of nanocarriers to target specific cells in the body remains the most difficult challenge. Systemically administered LNPs can access organs in which the capillaries are characterized by the presence of fenestrations, such as the liver and spleen. The liver has received the most attention to date, although targeted delivery to the spleen has recently emerged as a promising tool for modulating the immune system. In this review, we discuss recent advances in the use of LNPs for cell-specific targeted delivery of nucleic acids. We focus mainly on targeting liver hepatocytes and spleen immune cells as excellent targets for gene therapy. We also discuss the potential of endothelial cells as an alternate approach for targeting organs with a continuous endothelium.</p>

Journal

Citations (6)*help

See more

References(94)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top